Inside Health Policy

InsideHealthPolicy.com is a subscription-based online service that provides daily news updates and newsletters from Inside Washington Publishers, a company that has been delivering insider information from Washington, DC for over 30 years. The site is regularly refreshed with articles from our newsletter team, including Health Exchange Alert, Inside CMS, and FDA Week. It also features daily Short Takes and curated documents, all organized in a fully searchable archive. Users can explore dedicated sections on various topics such as health reform, Congress, Medicare, drug policies, and food safety. Additionally, subscribers receive a Morning Headlines email alert every business day, ensuring they stay informed about important news right from the start of their day.

National, Trade/B2B

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#1070123

United States

#252802

Law and Government/Government

#4716

Traffic sources

Monthly visitors

Articles

Rare Disease Group Slams Cancellation Of Newborn Screening Ad Comm

14 hours ago | insidehealthpolicy.com | Jessica Karins

The abrupt termination of a Health Resources and Services Administration (HRSA) advisory committee raised concerns about the future role of advisory panels around HHS, coming as the department also signals it could make changes to committees’ membership.
Second Potential mRNA Vaccine For Avian Flu In Development

15 hours ago | insidehealthpolicy.com | Jessica Karins

United Kingdom-based DIOSynVax and Singapore-based ACM Biolabs are collaborating on development of a next-generation avian influenza vaccine that could combat a potential pandemic, the companies announced Tuesday (April 22).
Novavax Says FDA Has Requested Post-Market Study On COVID Vaccine

1 day ago | insidehealthpolicy.com | Jessica Karins

Novavax announced FDA is seeking additional postmarketing commitments on its protein-based COVID-19 vaccine, after high-level FDA officials took the unusual step of delaying the full approval of the shot, which has been broadly administered under emergency use authorization since 2022.
Major Pharma, Tobacco Critic Dick Durbin To Retire From Congress

1 day ago | insidehealthpolicy.com | Jessica Karins

Senate Democratic Whip Dick Durbin (D-IL), a longtime advocate for reducing drug prices and the author of the 2009 law giving FDA authority to regulate tobacco, has announced he will not seek reelection for another term in 2026.
DOL Urged To Expand Biden-Era Reg To Stop Copay Assistance Exploitation

2 days ago | insidehealthpolicy.com | Gabrielle Wanneh

Advocates for patients with severe chronic conditions are calling on the Trump administration to block insurers, pharmacy benefit managers and other third-party vendors from designating certain drugs covered by CMS as “non-essential” to evade adhering to Affordable Care Act cost-sharing limits.
FDA Will Ban Two Rarely Used Food Dyes, Work With Industry On Others

2 days ago | insidehealthpolicy.com | Jessica Karins

HHS’ actions to begin removing synthetic food dyes will begin with revoking the authorizations of two rarely used dyes, while the department says it will work with the food industry on phasing out the more commonly used food dyes and move toward authorizing natural alternatives. After teasing the pending policy change , Monday (April 21), FDA said Tuesday (April 22) its plans include setting a national timeline for the food industry to transition from synthetic dyes to natural alternatives. Its...
Harvard University Tells Court: NIH Grant Cuts ‘Slam The Breaks’ On Disease Cures

2 days ago | insidehealthpolicy.com | Jessica Karins

Harvard University is the latest plaintiff to file a case against the Trump administration over its disruptions of federal funding, telling a federal court late Monday (April 21) the administration is “slamming the breaks” on cures for diseases by withholding over $2.2 billion in funding that has nothing to do with Harvard’s disputed diversity and civil-rights policies.
OPM Issues Rule Reclassifying Some Civil Servants For Potential Firings

3 days ago | insidehealthpolicy.com | Gabrielle Wanneh

The Office of Personnel Management is issuing a rule cleared by the Office of Management and Budget Friday (April 18) that will cement the creation of a new category of federal workers designed to identify members of the workforce the administration is likely to fire as it continues to sweep house of government jobs and offices it views as unnecessary or in opposition to its policymaking goals. The OPM rule would specifically set up a new “Schedule Policy/Career” category of...
Kennedy & Makary To Announce Ban On Synthetic Food Dyes

3 days ago | insidehealthpolicy.com | Jessica Karins |Maaisha Osman

HHS is set to announce Tuesday (April 22) an FDA effort to ban use of petroleum-based synthetic food dyes, the agency said, a major shift on food policy from the Trump administration that’s likely to meet with opposition from industry. HHS did not share details of the policy change but said HHS Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary will announce it Tuesday at HHS’ headquarters, and added the plan will mark “a major step forward in...
FDA Guidances Advance To OMB Amid Plans To Deregulate

3 days ago | insidehealthpolicy.com | Jessica Karins

Two FDA proposed guidance documents on reducing the risks of cell and tissue products have been sent to the White House budget office for review, the first FDA regulatory documents to advance to the Office of Management and Budget since the Trump administration began its regulatory freeze. It’s a possible sign the administration could be returning to more normal procedures for FDA guidance documents, as the submissions came a day before agencies’ deadline to submit plans to reduce the number...